A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis

NCT05414201 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-infectious Intermediate Posterior- or Pan-uveitis

Interventions

DRUG: Adalimumab

Sponsor

AbbVie